Global Atovaquone

Atovaquone Comprehensive Study by Type (750mg, 5mL Oral suspension, 250mg/100mg, 62.5mg/25mg), Application (Ant malarial treatment, Pneumonia (Pneumocystis carinii), Others), Distribution Channel (Online Pharmacy, Medical stores, Hospital pharmacy), Patient type (Adult, Pediatric), Dosage form (Tablets (Film-coated tablet), Suspension), End User (Hospital, Drug store, Government organizations) Players and Region - Global Market Outlook to 2024

Atovaquone Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Atovaquone?
Atovaquone is a chemical compound categorized into a class of naphthoquinones. It is mainly used in combination drugs such as Atovaquone-Proguanil for the treatment of malarial. Also used in the treatment of pneumonia. It is available in the suspension, tablet forms. The dosage is given according to the type of patient.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledGSK (United Kingdom), Pfizer (United States), Sanofi Aventis (France), Lupin (India), Apotex (Canada), Amneal Pharmaceuticals (United States), Glenmark (India), IPCA Laboratories (India), Dr. Reddy's Laboratories (India) and AstraZeneca (United Kingdom)


The study covers a detailed analysis segmented by key business segments i.e. by type (750mg, 5mL Oral suspension, 250mg/100mg and 62.5mg/25mg) , by application (Ant malarial treatment, Pneumonia (Pneumocystis carinii) and Others) and major geographies.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Atovaquone market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are GSK (United Kingdom), Pfizer (United States), Sanofi Aventis (France), Lupin (India), Apotex (Canada), Amneal Pharmaceuticals (United States), Glenmark (India), IPCA Laboratories (India), Dr. Reddy's Laboratories (India) and AstraZeneca (United Kingdom).

Market Overview:
On 24th February 2020, Clover and GSK partnered for research and evaluation coronavirus (COVID-19) vaccine candidate with the pandemic adjuvant system. Clover is a Chinese biopharmaceutical company announced its collaboration with GSK to empower vaccine for trending coronavirus.

The growing malarial infection and pneumonia infection results in increasing demand for the above product. The top leading firms are having their monopoly in the market they have competition and rivalry between them. The mergers and acquisitions are open options to enhance the strategical equations in the market. The companies also, launching their advance products to access the health of patients.

Influencing Trend:
Atovaquone-Proguanil is highly used for anti-malarial treatment

Market Growth Drivers:
Growing demand for malarial treatment and Increasing no of Pneumonia patients worldwide

Challenges:
Overdoses cause various harms to the body

Restraints:
Problems like severe or uncontrolled vomiting or diarrhea and more side effects are seen

Opportunities:
Growing production of generic Atovaquone dosage

Key highlights of the Global Atovaquone market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Atovaquone market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Atovaquone market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Atovaquone Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Atovaquone market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Atovaquone market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers, Hospital and diagnostic centres, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Industry Associate and Downstream Vendors.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • 750mg
  • 5mL Oral suspension
  • 250mg/100mg
  • 62.5mg/25mg
By Application
  • Ant malarial treatment
  • Pneumonia (Pneumocystis carinii)
  • Others
By Distribution Channel
  • Online Pharmacy
  • Medical stores
  • Hospital pharmacy

By Patient type
  • Adult
  • Pediatric

By Dosage form
  • Tablets (Film-coated tablet)
  • Suspension

By End User
  • Hospital
  • Drug store
  • Government organizations

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing demand for malarial treatment
      • 3.2.2. Increasing no of Pneumonia patients worldwide
    • 3.3. Market Challenges
      • 3.3.1. Overdoses cause various harms to the body
    • 3.4. Market Trends
      • 3.4.1. Atovaquone-Proguanil is highly used for anti-malarial treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Atovaquone, by Type, Application, Distribution Channel, Patient type , Dosage form, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Atovaquone (Value)
      • 5.2.1. Global Atovaquone by: Type (Value)
        • 5.2.1.1. 750mg
        • 5.2.1.2. 5mL Oral suspension
        • 5.2.1.3. 250mg/100mg
        • 5.2.1.4. 62.5mg/25mg
      • 5.2.2. Global Atovaquone by: Application (Value)
        • 5.2.2.1. Ant malarial treatment
        • 5.2.2.2. Pneumonia (Pneumocystis carinii)
        • 5.2.2.3. Others
      • 5.2.3. Global Atovaquone by: Distribution Channel (Value)
        • 5.2.3.1. Online Pharmacy
        • 5.2.3.2. Medical stores
        • 5.2.3.3. Hospital pharmacy
      • 5.2.4. Global Atovaquone by: Dosage form (Value)
        • 5.2.4.1. Tablets (Film-coated tablet)
        • 5.2.4.2. Suspension
      • 5.2.5. Global Atovaquone by: End User (Value)
        • 5.2.5.1. Hospital
        • 5.2.5.2. Drug store
        • 5.2.5.3. Government organizations
      • 5.2.6. Global Atovaquone Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Atovaquone: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GSK (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi Aventis (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lupin (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apotex (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amneal Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Glenmark (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. IPCA Laboratories (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddy's Laboratories (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Atovaquone Sale, by Type, Application, Distribution Channel, Patient type , Dosage form, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Atovaquone (Value)
      • 7.2.1. Global Atovaquone by: Type (Value)
        • 7.2.1.1. 750mg
        • 7.2.1.2. 5mL Oral suspension
        • 7.2.1.3. 250mg/100mg
        • 7.2.1.4. 62.5mg/25mg
      • 7.2.2. Global Atovaquone by: Application (Value)
        • 7.2.2.1. Ant malarial treatment
        • 7.2.2.2. Pneumonia (Pneumocystis carinii)
        • 7.2.2.3. Others
      • 7.2.3. Global Atovaquone by: Distribution Channel (Value)
        • 7.2.3.1. Online Pharmacy
        • 7.2.3.2. Medical stores
        • 7.2.3.3. Hospital pharmacy
      • 7.2.4. Global Atovaquone by: Dosage form (Value)
        • 7.2.4.1. Tablets (Film-coated tablet)
        • 7.2.4.2. Suspension
      • 7.2.5. Global Atovaquone by: End User (Value)
        • 7.2.5.1. Hospital
        • 7.2.5.2. Drug store
        • 7.2.5.3. Government organizations
      • 7.2.6. Global Atovaquone Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Atovaquone: by Type(USD Million)
  • Table 2. Atovaquone 750mg , by Region USD Million (2016-2021)
  • Table 3. Atovaquone 5mL Oral suspension , by Region USD Million (2016-2021)
  • Table 4. Atovaquone 250mg/100mg , by Region USD Million (2016-2021)
  • Table 5. Atovaquone 62.5mg/25mg , by Region USD Million (2016-2021)
  • Table 6. Atovaquone: by Application(USD Million)
  • Table 7. Atovaquone Ant malarial treatment , by Region USD Million (2016-2021)
  • Table 8. Atovaquone Pneumonia (Pneumocystis carinii) , by Region USD Million (2016-2021)
  • Table 9. Atovaquone Others , by Region USD Million (2016-2021)
  • Table 10. Atovaquone: by Distribution Channel(USD Million)
  • Table 11. Atovaquone Online Pharmacy , by Region USD Million (2016-2021)
  • Table 12. Atovaquone Medical stores , by Region USD Million (2016-2021)
  • Table 13. Atovaquone Hospital pharmacy , by Region USD Million (2016-2021)
  • Table 14. Atovaquone: by Dosage form(USD Million)
  • Table 15. Atovaquone Tablets (Film-coated tablet) , by Region USD Million (2016-2021)
  • Table 16. Atovaquone Suspension , by Region USD Million (2016-2021)
  • Table 17. Atovaquone: by End User(USD Million)
  • Table 18. Atovaquone Hospital , by Region USD Million (2016-2021)
  • Table 19. Atovaquone Drug store , by Region USD Million (2016-2021)
  • Table 20. Atovaquone Government organizations , by Region USD Million (2016-2021)
  • Table 21. South America Atovaquone, by Country USD Million (2016-2021)
  • Table 22. South America Atovaquone, by Type USD Million (2016-2021)
  • Table 23. South America Atovaquone, by Application USD Million (2016-2021)
  • Table 24. South America Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 25. South America Atovaquone, by Patient type USD Million (2016-2021)
  • Table 26. South America Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 27. South America Atovaquone, by End User USD Million (2016-2021)
  • Table 28. Brazil Atovaquone, by Type USD Million (2016-2021)
  • Table 29. Brazil Atovaquone, by Application USD Million (2016-2021)
  • Table 30. Brazil Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 31. Brazil Atovaquone, by Patient type USD Million (2016-2021)
  • Table 32. Brazil Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 33. Brazil Atovaquone, by End User USD Million (2016-2021)
  • Table 34. Argentina Atovaquone, by Type USD Million (2016-2021)
  • Table 35. Argentina Atovaquone, by Application USD Million (2016-2021)
  • Table 36. Argentina Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 37. Argentina Atovaquone, by Patient type USD Million (2016-2021)
  • Table 38. Argentina Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 39. Argentina Atovaquone, by End User USD Million (2016-2021)
  • Table 40. Rest of South America Atovaquone, by Type USD Million (2016-2021)
  • Table 41. Rest of South America Atovaquone, by Application USD Million (2016-2021)
  • Table 42. Rest of South America Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 43. Rest of South America Atovaquone, by Patient type USD Million (2016-2021)
  • Table 44. Rest of South America Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 45. Rest of South America Atovaquone, by End User USD Million (2016-2021)
  • Table 46. Asia Pacific Atovaquone, by Country USD Million (2016-2021)
  • Table 47. Asia Pacific Atovaquone, by Type USD Million (2016-2021)
  • Table 48. Asia Pacific Atovaquone, by Application USD Million (2016-2021)
  • Table 49. Asia Pacific Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 50. Asia Pacific Atovaquone, by Patient type USD Million (2016-2021)
  • Table 51. Asia Pacific Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 52. Asia Pacific Atovaquone, by End User USD Million (2016-2021)
  • Table 53. China Atovaquone, by Type USD Million (2016-2021)
  • Table 54. China Atovaquone, by Application USD Million (2016-2021)
  • Table 55. China Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 56. China Atovaquone, by Patient type USD Million (2016-2021)
  • Table 57. China Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 58. China Atovaquone, by End User USD Million (2016-2021)
  • Table 59. Japan Atovaquone, by Type USD Million (2016-2021)
  • Table 60. Japan Atovaquone, by Application USD Million (2016-2021)
  • Table 61. Japan Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 62. Japan Atovaquone, by Patient type USD Million (2016-2021)
  • Table 63. Japan Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 64. Japan Atovaquone, by End User USD Million (2016-2021)
  • Table 65. India Atovaquone, by Type USD Million (2016-2021)
  • Table 66. India Atovaquone, by Application USD Million (2016-2021)
  • Table 67. India Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 68. India Atovaquone, by Patient type USD Million (2016-2021)
  • Table 69. India Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 70. India Atovaquone, by End User USD Million (2016-2021)
  • Table 71. South Korea Atovaquone, by Type USD Million (2016-2021)
  • Table 72. South Korea Atovaquone, by Application USD Million (2016-2021)
  • Table 73. South Korea Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 74. South Korea Atovaquone, by Patient type USD Million (2016-2021)
  • Table 75. South Korea Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 76. South Korea Atovaquone, by End User USD Million (2016-2021)
  • Table 77. Taiwan Atovaquone, by Type USD Million (2016-2021)
  • Table 78. Taiwan Atovaquone, by Application USD Million (2016-2021)
  • Table 79. Taiwan Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 80. Taiwan Atovaquone, by Patient type USD Million (2016-2021)
  • Table 81. Taiwan Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 82. Taiwan Atovaquone, by End User USD Million (2016-2021)
  • Table 83. Australia Atovaquone, by Type USD Million (2016-2021)
  • Table 84. Australia Atovaquone, by Application USD Million (2016-2021)
  • Table 85. Australia Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 86. Australia Atovaquone, by Patient type USD Million (2016-2021)
  • Table 87. Australia Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 88. Australia Atovaquone, by End User USD Million (2016-2021)
  • Table 89. Rest of Asia-Pacific Atovaquone, by Type USD Million (2016-2021)
  • Table 90. Rest of Asia-Pacific Atovaquone, by Application USD Million (2016-2021)
  • Table 91. Rest of Asia-Pacific Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 92. Rest of Asia-Pacific Atovaquone, by Patient type USD Million (2016-2021)
  • Table 93. Rest of Asia-Pacific Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 94. Rest of Asia-Pacific Atovaquone, by End User USD Million (2016-2021)
  • Table 95. Europe Atovaquone, by Country USD Million (2016-2021)
  • Table 96. Europe Atovaquone, by Type USD Million (2016-2021)
  • Table 97. Europe Atovaquone, by Application USD Million (2016-2021)
  • Table 98. Europe Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 99. Europe Atovaquone, by Patient type USD Million (2016-2021)
  • Table 100. Europe Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 101. Europe Atovaquone, by End User USD Million (2016-2021)
  • Table 102. Germany Atovaquone, by Type USD Million (2016-2021)
  • Table 103. Germany Atovaquone, by Application USD Million (2016-2021)
  • Table 104. Germany Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 105. Germany Atovaquone, by Patient type USD Million (2016-2021)
  • Table 106. Germany Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 107. Germany Atovaquone, by End User USD Million (2016-2021)
  • Table 108. France Atovaquone, by Type USD Million (2016-2021)
  • Table 109. France Atovaquone, by Application USD Million (2016-2021)
  • Table 110. France Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 111. France Atovaquone, by Patient type USD Million (2016-2021)
  • Table 112. France Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 113. France Atovaquone, by End User USD Million (2016-2021)
  • Table 114. Italy Atovaquone, by Type USD Million (2016-2021)
  • Table 115. Italy Atovaquone, by Application USD Million (2016-2021)
  • Table 116. Italy Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 117. Italy Atovaquone, by Patient type USD Million (2016-2021)
  • Table 118. Italy Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 119. Italy Atovaquone, by End User USD Million (2016-2021)
  • Table 120. United Kingdom Atovaquone, by Type USD Million (2016-2021)
  • Table 121. United Kingdom Atovaquone, by Application USD Million (2016-2021)
  • Table 122. United Kingdom Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 123. United Kingdom Atovaquone, by Patient type USD Million (2016-2021)
  • Table 124. United Kingdom Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 125. United Kingdom Atovaquone, by End User USD Million (2016-2021)
  • Table 126. Netherlands Atovaquone, by Type USD Million (2016-2021)
  • Table 127. Netherlands Atovaquone, by Application USD Million (2016-2021)
  • Table 128. Netherlands Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 129. Netherlands Atovaquone, by Patient type USD Million (2016-2021)
  • Table 130. Netherlands Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 131. Netherlands Atovaquone, by End User USD Million (2016-2021)
  • Table 132. Rest of Europe Atovaquone, by Type USD Million (2016-2021)
  • Table 133. Rest of Europe Atovaquone, by Application USD Million (2016-2021)
  • Table 134. Rest of Europe Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 135. Rest of Europe Atovaquone, by Patient type USD Million (2016-2021)
  • Table 136. Rest of Europe Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 137. Rest of Europe Atovaquone, by End User USD Million (2016-2021)
  • Table 138. MEA Atovaquone, by Country USD Million (2016-2021)
  • Table 139. MEA Atovaquone, by Type USD Million (2016-2021)
  • Table 140. MEA Atovaquone, by Application USD Million (2016-2021)
  • Table 141. MEA Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 142. MEA Atovaquone, by Patient type USD Million (2016-2021)
  • Table 143. MEA Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 144. MEA Atovaquone, by End User USD Million (2016-2021)
  • Table 145. Middle East Atovaquone, by Type USD Million (2016-2021)
  • Table 146. Middle East Atovaquone, by Application USD Million (2016-2021)
  • Table 147. Middle East Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 148. Middle East Atovaquone, by Patient type USD Million (2016-2021)
  • Table 149. Middle East Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 150. Middle East Atovaquone, by End User USD Million (2016-2021)
  • Table 151. Africa Atovaquone, by Type USD Million (2016-2021)
  • Table 152. Africa Atovaquone, by Application USD Million (2016-2021)
  • Table 153. Africa Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 154. Africa Atovaquone, by Patient type USD Million (2016-2021)
  • Table 155. Africa Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 156. Africa Atovaquone, by End User USD Million (2016-2021)
  • Table 157. North America Atovaquone, by Country USD Million (2016-2021)
  • Table 158. North America Atovaquone, by Type USD Million (2016-2021)
  • Table 159. North America Atovaquone, by Application USD Million (2016-2021)
  • Table 160. North America Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 161. North America Atovaquone, by Patient type USD Million (2016-2021)
  • Table 162. North America Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 163. North America Atovaquone, by End User USD Million (2016-2021)
  • Table 164. United States Atovaquone, by Type USD Million (2016-2021)
  • Table 165. United States Atovaquone, by Application USD Million (2016-2021)
  • Table 166. United States Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 167. United States Atovaquone, by Patient type USD Million (2016-2021)
  • Table 168. United States Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 169. United States Atovaquone, by End User USD Million (2016-2021)
  • Table 170. Canada Atovaquone, by Type USD Million (2016-2021)
  • Table 171. Canada Atovaquone, by Application USD Million (2016-2021)
  • Table 172. Canada Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 173. Canada Atovaquone, by Patient type USD Million (2016-2021)
  • Table 174. Canada Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 175. Canada Atovaquone, by End User USD Million (2016-2021)
  • Table 176. Mexico Atovaquone, by Type USD Million (2016-2021)
  • Table 177. Mexico Atovaquone, by Application USD Million (2016-2021)
  • Table 178. Mexico Atovaquone, by Distribution Channel USD Million (2016-2021)
  • Table 179. Mexico Atovaquone, by Patient type USD Million (2016-2021)
  • Table 180. Mexico Atovaquone, by Dosage form USD Million (2016-2021)
  • Table 181. Mexico Atovaquone, by End User USD Million (2016-2021)
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Company Basic Information, Sales Area and Its Competitors
  • Table 184. Company Basic Information, Sales Area and Its Competitors
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Atovaquone: by Type(USD Million)
  • Table 193. Atovaquone 750mg , by Region USD Million (2022-2027)
  • Table 194. Atovaquone 5mL Oral suspension , by Region USD Million (2022-2027)
  • Table 195. Atovaquone 250mg/100mg , by Region USD Million (2022-2027)
  • Table 196. Atovaquone 62.5mg/25mg , by Region USD Million (2022-2027)
  • Table 197. Atovaquone: by Application(USD Million)
  • Table 198. Atovaquone Ant malarial treatment , by Region USD Million (2022-2027)
  • Table 199. Atovaquone Pneumonia (Pneumocystis carinii) , by Region USD Million (2022-2027)
  • Table 200. Atovaquone Others , by Region USD Million (2022-2027)
  • Table 201. Atovaquone: by Distribution Channel(USD Million)
  • Table 202. Atovaquone Online Pharmacy , by Region USD Million (2022-2027)
  • Table 203. Atovaquone Medical stores , by Region USD Million (2022-2027)
  • Table 204. Atovaquone Hospital pharmacy , by Region USD Million (2022-2027)
  • Table 205. Atovaquone: by Dosage form(USD Million)
  • Table 206. Atovaquone Tablets (Film-coated tablet) , by Region USD Million (2022-2027)
  • Table 207. Atovaquone Suspension , by Region USD Million (2022-2027)
  • Table 208. Atovaquone: by End User(USD Million)
  • Table 209. Atovaquone Hospital , by Region USD Million (2022-2027)
  • Table 210. Atovaquone Drug store , by Region USD Million (2022-2027)
  • Table 211. Atovaquone Government organizations , by Region USD Million (2022-2027)
  • Table 212. South America Atovaquone, by Country USD Million (2022-2027)
  • Table 213. South America Atovaquone, by Type USD Million (2022-2027)
  • Table 214. South America Atovaquone, by Application USD Million (2022-2027)
  • Table 215. South America Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 216. South America Atovaquone, by Patient type USD Million (2022-2027)
  • Table 217. South America Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 218. South America Atovaquone, by End User USD Million (2022-2027)
  • Table 219. Brazil Atovaquone, by Type USD Million (2022-2027)
  • Table 220. Brazil Atovaquone, by Application USD Million (2022-2027)
  • Table 221. Brazil Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 222. Brazil Atovaquone, by Patient type USD Million (2022-2027)
  • Table 223. Brazil Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 224. Brazil Atovaquone, by End User USD Million (2022-2027)
  • Table 225. Argentina Atovaquone, by Type USD Million (2022-2027)
  • Table 226. Argentina Atovaquone, by Application USD Million (2022-2027)
  • Table 227. Argentina Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 228. Argentina Atovaquone, by Patient type USD Million (2022-2027)
  • Table 229. Argentina Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 230. Argentina Atovaquone, by End User USD Million (2022-2027)
  • Table 231. Rest of South America Atovaquone, by Type USD Million (2022-2027)
  • Table 232. Rest of South America Atovaquone, by Application USD Million (2022-2027)
  • Table 233. Rest of South America Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 234. Rest of South America Atovaquone, by Patient type USD Million (2022-2027)
  • Table 235. Rest of South America Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 236. Rest of South America Atovaquone, by End User USD Million (2022-2027)
  • Table 237. Asia Pacific Atovaquone, by Country USD Million (2022-2027)
  • Table 238. Asia Pacific Atovaquone, by Type USD Million (2022-2027)
  • Table 239. Asia Pacific Atovaquone, by Application USD Million (2022-2027)
  • Table 240. Asia Pacific Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 241. Asia Pacific Atovaquone, by Patient type USD Million (2022-2027)
  • Table 242. Asia Pacific Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 243. Asia Pacific Atovaquone, by End User USD Million (2022-2027)
  • Table 244. China Atovaquone, by Type USD Million (2022-2027)
  • Table 245. China Atovaquone, by Application USD Million (2022-2027)
  • Table 246. China Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 247. China Atovaquone, by Patient type USD Million (2022-2027)
  • Table 248. China Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 249. China Atovaquone, by End User USD Million (2022-2027)
  • Table 250. Japan Atovaquone, by Type USD Million (2022-2027)
  • Table 251. Japan Atovaquone, by Application USD Million (2022-2027)
  • Table 252. Japan Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 253. Japan Atovaquone, by Patient type USD Million (2022-2027)
  • Table 254. Japan Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 255. Japan Atovaquone, by End User USD Million (2022-2027)
  • Table 256. India Atovaquone, by Type USD Million (2022-2027)
  • Table 257. India Atovaquone, by Application USD Million (2022-2027)
  • Table 258. India Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 259. India Atovaquone, by Patient type USD Million (2022-2027)
  • Table 260. India Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 261. India Atovaquone, by End User USD Million (2022-2027)
  • Table 262. South Korea Atovaquone, by Type USD Million (2022-2027)
  • Table 263. South Korea Atovaquone, by Application USD Million (2022-2027)
  • Table 264. South Korea Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 265. South Korea Atovaquone, by Patient type USD Million (2022-2027)
  • Table 266. South Korea Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 267. South Korea Atovaquone, by End User USD Million (2022-2027)
  • Table 268. Taiwan Atovaquone, by Type USD Million (2022-2027)
  • Table 269. Taiwan Atovaquone, by Application USD Million (2022-2027)
  • Table 270. Taiwan Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 271. Taiwan Atovaquone, by Patient type USD Million (2022-2027)
  • Table 272. Taiwan Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 273. Taiwan Atovaquone, by End User USD Million (2022-2027)
  • Table 274. Australia Atovaquone, by Type USD Million (2022-2027)
  • Table 275. Australia Atovaquone, by Application USD Million (2022-2027)
  • Table 276. Australia Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 277. Australia Atovaquone, by Patient type USD Million (2022-2027)
  • Table 278. Australia Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 279. Australia Atovaquone, by End User USD Million (2022-2027)
  • Table 280. Rest of Asia-Pacific Atovaquone, by Type USD Million (2022-2027)
  • Table 281. Rest of Asia-Pacific Atovaquone, by Application USD Million (2022-2027)
  • Table 282. Rest of Asia-Pacific Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 283. Rest of Asia-Pacific Atovaquone, by Patient type USD Million (2022-2027)
  • Table 284. Rest of Asia-Pacific Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 285. Rest of Asia-Pacific Atovaquone, by End User USD Million (2022-2027)
  • Table 286. Europe Atovaquone, by Country USD Million (2022-2027)
  • Table 287. Europe Atovaquone, by Type USD Million (2022-2027)
  • Table 288. Europe Atovaquone, by Application USD Million (2022-2027)
  • Table 289. Europe Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 290. Europe Atovaquone, by Patient type USD Million (2022-2027)
  • Table 291. Europe Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 292. Europe Atovaquone, by End User USD Million (2022-2027)
  • Table 293. Germany Atovaquone, by Type USD Million (2022-2027)
  • Table 294. Germany Atovaquone, by Application USD Million (2022-2027)
  • Table 295. Germany Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 296. Germany Atovaquone, by Patient type USD Million (2022-2027)
  • Table 297. Germany Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 298. Germany Atovaquone, by End User USD Million (2022-2027)
  • Table 299. France Atovaquone, by Type USD Million (2022-2027)
  • Table 300. France Atovaquone, by Application USD Million (2022-2027)
  • Table 301. France Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 302. France Atovaquone, by Patient type USD Million (2022-2027)
  • Table 303. France Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 304. France Atovaquone, by End User USD Million (2022-2027)
  • Table 305. Italy Atovaquone, by Type USD Million (2022-2027)
  • Table 306. Italy Atovaquone, by Application USD Million (2022-2027)
  • Table 307. Italy Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 308. Italy Atovaquone, by Patient type USD Million (2022-2027)
  • Table 309. Italy Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 310. Italy Atovaquone, by End User USD Million (2022-2027)
  • Table 311. United Kingdom Atovaquone, by Type USD Million (2022-2027)
  • Table 312. United Kingdom Atovaquone, by Application USD Million (2022-2027)
  • Table 313. United Kingdom Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 314. United Kingdom Atovaquone, by Patient type USD Million (2022-2027)
  • Table 315. United Kingdom Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 316. United Kingdom Atovaquone, by End User USD Million (2022-2027)
  • Table 317. Netherlands Atovaquone, by Type USD Million (2022-2027)
  • Table 318. Netherlands Atovaquone, by Application USD Million (2022-2027)
  • Table 319. Netherlands Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 320. Netherlands Atovaquone, by Patient type USD Million (2022-2027)
  • Table 321. Netherlands Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 322. Netherlands Atovaquone, by End User USD Million (2022-2027)
  • Table 323. Rest of Europe Atovaquone, by Type USD Million (2022-2027)
  • Table 324. Rest of Europe Atovaquone, by Application USD Million (2022-2027)
  • Table 325. Rest of Europe Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 326. Rest of Europe Atovaquone, by Patient type USD Million (2022-2027)
  • Table 327. Rest of Europe Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 328. Rest of Europe Atovaquone, by End User USD Million (2022-2027)
  • Table 329. MEA Atovaquone, by Country USD Million (2022-2027)
  • Table 330. MEA Atovaquone, by Type USD Million (2022-2027)
  • Table 331. MEA Atovaquone, by Application USD Million (2022-2027)
  • Table 332. MEA Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 333. MEA Atovaquone, by Patient type USD Million (2022-2027)
  • Table 334. MEA Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 335. MEA Atovaquone, by End User USD Million (2022-2027)
  • Table 336. Middle East Atovaquone, by Type USD Million (2022-2027)
  • Table 337. Middle East Atovaquone, by Application USD Million (2022-2027)
  • Table 338. Middle East Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 339. Middle East Atovaquone, by Patient type USD Million (2022-2027)
  • Table 340. Middle East Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 341. Middle East Atovaquone, by End User USD Million (2022-2027)
  • Table 342. Africa Atovaquone, by Type USD Million (2022-2027)
  • Table 343. Africa Atovaquone, by Application USD Million (2022-2027)
  • Table 344. Africa Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 345. Africa Atovaquone, by Patient type USD Million (2022-2027)
  • Table 346. Africa Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 347. Africa Atovaquone, by End User USD Million (2022-2027)
  • Table 348. North America Atovaquone, by Country USD Million (2022-2027)
  • Table 349. North America Atovaquone, by Type USD Million (2022-2027)
  • Table 350. North America Atovaquone, by Application USD Million (2022-2027)
  • Table 351. North America Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 352. North America Atovaquone, by Patient type USD Million (2022-2027)
  • Table 353. North America Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 354. North America Atovaquone, by End User USD Million (2022-2027)
  • Table 355. United States Atovaquone, by Type USD Million (2022-2027)
  • Table 356. United States Atovaquone, by Application USD Million (2022-2027)
  • Table 357. United States Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 358. United States Atovaquone, by Patient type USD Million (2022-2027)
  • Table 359. United States Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 360. United States Atovaquone, by End User USD Million (2022-2027)
  • Table 361. Canada Atovaquone, by Type USD Million (2022-2027)
  • Table 362. Canada Atovaquone, by Application USD Million (2022-2027)
  • Table 363. Canada Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 364. Canada Atovaquone, by Patient type USD Million (2022-2027)
  • Table 365. Canada Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 366. Canada Atovaquone, by End User USD Million (2022-2027)
  • Table 367. Mexico Atovaquone, by Type USD Million (2022-2027)
  • Table 368. Mexico Atovaquone, by Application USD Million (2022-2027)
  • Table 369. Mexico Atovaquone, by Distribution Channel USD Million (2022-2027)
  • Table 370. Mexico Atovaquone, by Patient type USD Million (2022-2027)
  • Table 371. Mexico Atovaquone, by Dosage form USD Million (2022-2027)
  • Table 372. Mexico Atovaquone, by End User USD Million (2022-2027)
  • Table 373. Research Programs/Design for This Report
  • Table 374. Key Data Information from Secondary Sources
  • Table 375. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Atovaquone: by Type USD Million (2016-2021)
  • Figure 5. Global Atovaquone: by Application USD Million (2016-2021)
  • Figure 6. Global Atovaquone: by Distribution Channel USD Million (2016-2021)
  • Figure 7. Global Atovaquone: by Dosage form USD Million (2016-2021)
  • Figure 8. Global Atovaquone: by End User USD Million (2016-2021)
  • Figure 9. South America Atovaquone Share (%), by Country
  • Figure 10. Asia Pacific Atovaquone Share (%), by Country
  • Figure 11. Europe Atovaquone Share (%), by Country
  • Figure 12. MEA Atovaquone Share (%), by Country
  • Figure 13. North America Atovaquone Share (%), by Country
  • Figure 14. Global Atovaquone share by Players 2021 (%)
  • Figure 15. Global Atovaquone share by Players (Top 3) 2021(%)
  • Figure 16. Global Atovaquone share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GSK (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GSK (United Kingdom) Revenue: by Geography 2021
  • Figure 20. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer (United States) Revenue: by Geography 2021
  • Figure 22. Sanofi Aventis (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi Aventis (France) Revenue: by Geography 2021
  • Figure 24. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 25. Lupin (India) Revenue: by Geography 2021
  • Figure 26. Apotex (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Apotex (Canada) Revenue: by Geography 2021
  • Figure 28. Amneal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amneal Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 30. Glenmark (India) Revenue, Net Income and Gross profit
  • Figure 31. Glenmark (India) Revenue: by Geography 2021
  • Figure 32. IPCA Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 33. IPCA Laboratories (India) Revenue: by Geography 2021
  • Figure 34. Dr. Reddy's Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 35. Dr. Reddy's Laboratories (India) Revenue: by Geography 2021
  • Figure 36. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 38. Global Atovaquone: by Type USD Million (2022-2027)
  • Figure 39. Global Atovaquone: by Application USD Million (2022-2027)
  • Figure 40. Global Atovaquone: by Distribution Channel USD Million (2022-2027)
  • Figure 41. Global Atovaquone: by Dosage form USD Million (2022-2027)
  • Figure 42. Global Atovaquone: by End User USD Million (2022-2027)
  • Figure 43. South America Atovaquone Share (%), by Country
  • Figure 44. Asia Pacific Atovaquone Share (%), by Country
  • Figure 45. Europe Atovaquone Share (%), by Country
  • Figure 46. MEA Atovaquone Share (%), by Country
  • Figure 47. North America Atovaquone Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GSK (United Kingdom)
  • Pfizer (United States)
  • Sanofi Aventis (France)
  • Lupin (India)
  • Apotex (Canada)
  • Amneal Pharmaceuticals (United States)
  • Glenmark (India)
  • IPCA Laboratories (India)
  • Dr. Reddy's Laboratories (India)
  • AstraZeneca (United Kingdom)
Select User Access Type

Key Highlights of Report


Mar 2020 235 Pages 86 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Atovaquone Quantitative research analysis
Global Atovaquone Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Atovaquone Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Atovaquone market is dominated by Players and may generate healthy valuation by 2027.
  • Growing demand for malarial treatment
  • Increasing no of Pneumonia patients worldwide
dominated the Atovaquone market. This is attributable to growing trend of "Atovaquone-Proguanil is highly used for anti-malarial treatment"

Know More About Global Atovaquone Report?

Have a Query? Click Here

Other Related Reports

Terbinafine Hydrochloride Drug Comprehensive Study by Application (Athlete's Foot, Jock Itch, Ringworm, Others), Route of Administration (Topical, Oral), Duration of therapy (Fingernail onychomycosis...
$ 3450
Specialty Supplements Comprehensive Study by Application (Skin Care, Hair Care, Nutritional Deficiency, Cardiac Care, Mind Care, Others), Sales (Online, Offline), Form (Liquid, Powder, Capsule), Ingr...
$ 3450
Commercial Pharmaceutical Analytics Comprehensive Study by Type (Descriptive analytics, Predictive analytics, Prescriptive analytics), Application (Research & Development, Marketing & Sales, Supply C...
$ 3450
Jojoba Oil Comprehensive Study by Type (Unrefined, Refined), Application (Cosmetics & Personal care, Pharmaceutical, Industrial, Others), Distribution Channel (Hypermarkets/Supermarkets, Convenience ...
$ 3350
Pharmaceutical Manufacturing Comprehensive Study by Type (Continuous, Batch processing), Prescription (Prescription Based Medicines, OTC (Over the Counter) Medicines), End Users (Neonates and Pediatr...
$ 3750
Controlled Release Drug Delivery Comprehensive Study by Type (Inhalers, Injectable, Others), Application (Hospitals & Clinics, Research Organisations), Route of Administration (Oral, Transdermal, Oth...
$ 3450